Deucravacitinib for genetic skin disorders
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic skin condition called epidermolysis bullosa (EBS) or certain types of ichthyosis (like keratinopathic ichthyosis or ECI).
- You must have at least 4 new blisters each day (if you have EBS) OR an ichthyosis severity score over 50 out of 128 (if you have ichthyosis).
- You agree to stop using any other skin treatments other than the ones the study doctor allows.
- You cannot have certain other genetic skin conditions like Netherton syndrome or KID syndrome.
- You must not have active infections or immune-related conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.